Pneumovax 23 (PPV23) is being discontinued from routine use in the UK. In response to this change, the BSI Clinical Immunology Professional Network (BSI-CIPN) has produced a short consensus statement on implications for immunodeficiency diagnosis and immunoglobulin access to help avoid unnecessary diagnostic delay or inequity of access to care.